Financial Analysis: Tabula Rasa Healthcare (TRHC) & Complete Genomics (GNOM)
Tabula Rasa Healthcare (NASDAQ: TRHC) and Complete Genomics (NASDAQ:GNOM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Valuation and Earnings
This table compares Tabula Rasa Healthcare and Complete Genomics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tabula Rasa Healthcare||$94.06 million||6.49||-$6.25 million||($0.25)||-136.80|
Insider and Institutional Ownership
31.9% of Tabula Rasa Healthcare shares are owned by institutional investors. 45.8% of Tabula Rasa Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Tabula Rasa Healthcare and Complete Genomics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tabula Rasa Healthcare||0||1||5||0||2.83|
Tabula Rasa Healthcare presently has a consensus price target of $28.33, indicating a potential downside of 17.15%. Given Tabula Rasa Healthcare’s higher probable upside, research analysts plainly believe Tabula Rasa Healthcare is more favorable than Complete Genomics.
This table compares Tabula Rasa Healthcare and Complete Genomics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tabula Rasa Healthcare||-2.27%||-5.58%||-3.49%|
Tabula Rasa Healthcare beats Complete Genomics on 6 of the 9 factors compared between the two stocks.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc. (Tabula Rasa), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help its clients to properly characterize a patient’s acuity, or severity of health condition, and optimize the associated payments for care. The Company serves approximately 100 healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. Its products and services are built around the Medication Risk Mitigation Matrix, or MRM Matrix.
Complete Genomics Company Profile
Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.